Healthequity (NASDAQ:HQY) Stock Rating Reaffirmed by Cantor Fitzgerald

Healthequity (NASDAQ:HQY)‘s stock had its “buy” rating reaffirmed by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Stock Target Advisor reports. They currently have a $95.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 44.95% from the stock’s current price.

Other analysts have also issued reports about the company. Zacks Investment Research raised Healthequity from a “sell” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Tuesday, November 5th. Raymond James raised Healthequity from an “outperform” rating to a “strong-buy” rating and reduced their target price for the stock from $90.00 to $80.00 in a report on Monday, September 9th. SunTrust Banks decreased their target price on Healthequity to $80.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Bank of America set a $79.00 price target on Healthequity and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, TheStreet downgraded Healthequity from a “b” rating to a “c+” rating in a report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $77.86.

HQY stock opened at $65.54 on Wednesday. The stock’s 50 day moving average is $60.18 and its two-hundred day moving average is $64.15. Healthequity has a 52-week low of $50.29 and a 52-week high of $85.07. The company has a market capitalization of $4.44 billion, a PE ratio of 68.99, a P/E/G ratio of 2.87 and a beta of 1.47. The company has a quick ratio of 22.98, a current ratio of 22.98 and a debt-to-equity ratio of 0.04.

Healthequity (NASDAQ:HQY) last released its earnings results on Tuesday, December 3rd. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.33. Healthequity had a return on equity of 11.77% and a net margin of 28.13%. The company had revenue of $157.12 million during the quarter, compared to analysts’ expectations of $152.38 million. During the same period in the prior year, the business posted $0.25 EPS. The business’s revenue was up 122.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Healthequity will post 0.87 EPS for the current year.

In related news, CFO Darcy G. Mott sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $61.61, for a total transaction of $246,440.00. Following the completion of the transaction, the chief financial officer now owns 46,000 shares in the company, valued at approximately $2,834,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 12,000 shares of company stock valued at $715,600 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in Healthequity by 13.1% in the 2nd quarter. BlackRock Inc. now owns 7,268,685 shares of the company’s stock worth $475,373,000 after buying an additional 840,177 shares in the last quarter. Renaissance Technologies LLC raised its stake in Healthequity by 76.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,162,234 shares of the company’s stock valued at $76,010,000 after acquiring an additional 504,700 shares in the last quarter. Nuveen Asset Management LLC acquired a new position in Healthequity during the 2nd quarter worth $30,550,000. D. E. Shaw & Co. Inc. grew its stake in shares of Healthequity by 1,745.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 476,201 shares of the company’s stock worth $31,144,000 after purchasing an additional 450,402 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Healthequity by 18.7% in the third quarter. State Street Corp now owns 2,189,161 shares of the company’s stock worth $125,100,000 after purchasing an additional 344,173 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Article: NASDAQ Stock Market Explained

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit